surmount-1 tirzepatide weight loss percent 72 weeks (ZEPBOUND) Approved for Chronic Management in Adults with Obesity ✨ The FDA has approved Zepbound (tirzepatide) for chronic weight management in adults with obesity (BMI of 30 kg/ m2 or SURMOUNT‐1 study design. This is

Tirzepatide is a breakthrough medication that has gained attention for its potential to assist with weight loss

It is not a traditional healthcare avenue for patients to seek treatment outside the established clinical guidelines of Weight Management

The results of these trials could substantially influence treatment guidelines and reimbursement policies for tirzepatide

What actually predicts how Ill feel: Deep sleep: r = +0.55 (moderate-strong positive) Resting heart rate: r = -0.82 (very strong negative) Turns out autonomic tone and sleep architecture matter far more than time in bed

The pink color serves as a visual indicator that your formulation contains B12

Pregnancy Tell your healthcare provider if you are pregnant or plan to become pregnant Tell your healthcare provider if you become pregnant while using MOUNJARO Limited data on MOUNJARO use in pregnant women are available to inform on drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes Based on animal reproduction studies, there may be risks to the fetus from exposure to MOUNJARO Use only if potential benefit justifies the potential risk to the fetus Lactation It is not known if MOUNJARO passes into your breast milk Talk to your healthcare provider about the best way to feed your baby while using MOUNJARO There are no data on the presence of MOUNJARO in human milk, the effects on the breastfed infant, or the effects on milk production